Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Neurotrophic factor therapy - Prospects and problems
Autore:
Apfel, SC;
Indirizzi:
Albert Einstein Coll Med, Kennedy Ctr 401, Bronx, NY 10461 USA Albert Einstein Coll Med Bronx NY USA 10461 Ctr 401, Bronx, NY 10461 USA
Titolo Testata:
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
fascicolo: 4, volume: 39, anno: 2001,
pagine: 351 - 355
SICI:
1434-6621(200104)39:4<351:NFT-PA>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
NERVE GROWTH-FACTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; PLACEBO-CONTROLLED TRIAL; FACTOR-I; DIABETIC POLYNEUROPATHY; DOPAMINERGIC-NEURONS; TOPICAL TREATMENT; MOTONEURONS; BRAIN; SURVIVAL;
Keywords:
neurotrophic factors; nerve growth factor; brain derived neurotrophic factor; neurotrophin-3; cholinergic neurotrophic factors; immunoglobulin factor-1 (IGF-1);
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
30
Recensione:
Indirizzi per estratti:
Indirizzo: Apfel, SC Albert Einstein Coll Med, Kennedy Ctr 401, 1300 Morris Pk Ave, Bronx, NY 10461 USA Albert Einstein Coll Med 1300 Morris Pk Ave Bronx NY USA10461 A
Citazione:
S.C. Apfel, "Neurotrophic factor therapy - Prospects and problems", CLIN CH L M, 39(4), 2001, pp. 351-355

Abstract

Over the past 15 years neurotrophic factors have generated considerable excitement for their potential as therapy for a wide variety of degenerative neurological disorders, for which there is currently no treatment. The first part of this period was marked by the discovery, characterization, and cloning of many new growth factors, and by successful testing of these factors in animal models of neurological disease. In recent years the biotechnology industry and pharmaceutical industry have attempted to replicate the success of the animal studies in clinical trials. Although some studies have demonstrated moderate efficacy, for the most part the clinical trials have been less successful at demonstrating the therapeutic efficacy of this new class of drugs. For example, nerve growth factor appeared to be efficacious in two phase II clinical trials for peripheral neuropathy, but failed in a large scale phase III trial. Ciliary neurotrophic factor, brain derived neurotrophic factor and insulin like growth factor-1 have all been tested in clinical trials for the treatment of amyotrophic lateral sclerosis, with at best, variable indications of efficacy. Nevertheless, there are still many reasons to be optimistic that some of these agents may be useful clinically. Many technical and pharmacological issues remain to be adequately addressed, before neurotrophic factors can live up to their potential. Our collective experience with them has re-adjusted previously wild expectations, so that they are now much more realistic. This is necessary and beneficial for the maturation of this field of study.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 15:09:30